2.08
-17.1803(-89.20%)
Currency In USD
Address
1167 Massachusetts Avenue
Arlington, MA 02476
United States of America
Phone
781 996 5252
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
38
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Mr. Todd Bazemore | Interim Chief Executive Officer, President & Chief Operating Officer | 732,507 | 1970 |
| Dr. R. Kim Brazzell Ph.D. | Head of R&D and Chief Medical Officer | 703,644 | 1953 |
| Mr. Josiah Craver | Senior Vice President & Corporate Controller | 0 | N/A |
| Ms. Jill S. Steier | Executive Director of Investor Relations & Corporate Communications | 0 | N/A |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor | 0 | N/A |
| Mr. Darius Kharabi J.D., M.B.A. | Chief Business Officer | 0 | 1980 |
| Mr. Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management | 0 | 1963 |
| Ms. Mary Reumuth CPA | Chief Financial Officer, Treasurer & Secretary | 0 | 1975 |
| Mr. Carl Rennie | Executive Director of Account Management | 0 | N/A |
| Dr. Justin Hanes Ph.D. | Founder & Chair of the Scientific Advisory Board | 0 | N/A |
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.